JPRN-UMIN000004474Not yet recruiting未知
KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy - KOBE-SPEED
Division of Cardiovascular Medicine , Department of Internal Medicine, Kobe University Graduate School of Medicine0 sites50 target enrollmentStarted: November 1, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Patients with Congestive Heart Failure 2. Creatinine or 2mg/dL 3. Patients on hemodialysis 4. Leukopenia drug ingredients for research hepatic dysfunction, severe side effects such as renal dysfunction, Patients with a history of hypersensitivity 5. Patients are pregnant or potentially pregnant women 6. Subacute patients with acute limb ischemia 7. Insulin-treated patients (Eg, insulin administration was started during the study will continue to study) 8. Patients with a history of adverse reactions to thiazolidinediones 9. Patients with severe liver dysfunction in renal function 10. The patient will be excluded from the safety of thiazolidinediones in terms of 11. In addition, at the discretion of the attending physician considered patient inappropriate for study
Investigators
Similar Trials
Recruiting
Phase 3
Evaluation of Effect of pioglitazone on decreasing of proteinuria in type II diabetic patients with nephropathy.Diabetic Nephropathy.E10.2Insulin-deIRCT2017080210222N10Vice chancellor for research of Shahrekord University of Medical Science60
Completed
Not Applicable
A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemiaISRCTN78563659Takeda Europe R and D Centre (UK)26
Active, not recruiting
Not Applicable
Pilot trial studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients with Type II Diabetes and Insulin Resistance undergoing elective PTCAEUCTR2006-002237-20-DETakeda Pharma GmbH
Recruiting
Not Applicable
Comparison of efficacy and safety of pioglitazone versus metformin for moderate-to-severe chronic plaque psoriasis in patients with prediabetes or newly-diagnosed diabetes who have never taken anti-diabetic agents: a parallel, randomized, open-label, prospective studypsoriasisprediabetesdiabetes mellitusplaquepsoriasisprediabetesdiabetes mellitusTCTR20190724005Dermatological Society of Thailand (pending)40
Completed
Phase 2
Study of efficacy and side effects of Pioglitazone in the treatment of psoriasisPsoriasis vulgarisPsoriasis.IRCT138903013862N2Research Council of Mashhad University of Medical Sciences26